ALTACE ® (ramipril)

• Co-promotion Agreement in U.S. with King Pharmaceuticals

• First ACE Inhibitor Shown to Significantly Reduce Cardiovascular Events in Patients at Risk for CVD

• New Indication Approved: October 5, 2000

  • Therapy to Significantly Reduce the Risk of:
    • Myocardial Infarction
    • Stroke
    • Cardiovascular Death
  • In Patients at Risk for Cardiovascular Disease

• Since Wyeth Launched in Early November New Rx’s Increased 35% to a 6.1% Share

HOPE Study Confirms Cardiovascular Benefit

Previous slide

Next slide

Back to first slide

View graphic version